Milan-based StarTric, a medtech startup, announced on Monday that it has secured funding in a new seed financing round from early-stage investors, including NLC Health Impact Fund, Growth Engine, and Business Angels.
The company will use the funds to advance its next-generation technology for the transcatheter repair of the tricuspid heart valve, addressing a critical need in cardiac care.
“The funds from this round will be used to finalise the design of a minimally invasive device that is aimed at treating TR with unprecedented efficacy, ability to be “personalised” to each patient, and ease of use. This milestone is of the utmost importance, as its achievement will pave the way to the production of the investigational device for the first-in-human trial”, says Daniele Zanotti, CEO of StarTric.
What is Tricuspid Regurgitation (TR)?
Tricuspid regurgitation (TR) is a serious heart condition that affects millions of people worldwide.
It is the leakage of blood backward through the tricuspid valve each time the right ventricle contracts.
However, it currently lacks effective and accessible treatment options.
And here’s where StarTric comes into play!
StarTric: Transforming tricuspid regurgitation treatment
StarTric develops a minimally invasive device addressing Tricuspid Regurgitation (TR).
The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique developed by the founders Prof. Ottavio Alfieri and Prof.Michele De Bonis.
As a result, it could significantly improve patient outcomes and reduce recovery times.
“We have achieved several key development milestones and received significant interest and appreciation within the interventional cardiology community at the recent EuroPCR conference. We are also very glad with the vote of confidence of our investors and the intense teamwork with our clinical partners to accelerate the company towards clinical use,” says Eugenio Passanante, founder and CFO.
The investor
The NLC Health Impact Fund is established to drive investments in early-stage innovations in healthcare.
The fund deploys capital towards ventures of varied maturity levels, providing initial and follow-on funding.
With the NLC Health Impact Fund, NLC provides investors with the opportunity to access a diversified portfolio of impactful healthtech ventures.
“StarTric’s technology is setting a new standard in the ability to treat tricuspid valve regurgitation, reducing the need for invasive surgeries while reproducing their clinical efficacy, thus lowering healthcare costs and improving patient care. We are excited to support StarTric as they progress towards the first-in-human trial and look forward to broad clinical adoption of this groundbreaking technology,” says Alessandro Radaelli, Venture Partner at NLC Health Ventures.
01
From port to startup fort: How Lars Crama is ‘Making it Happen’ in Rotterdam